Compare ESPR & PANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | PANL |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 543.2M |
| IPO Year | 2013 | 2015 |
| Metric | ESPR | PANL |
|---|---|---|
| Price | $2.65 | $6.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $7.60 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 5.0M | 678.8K |
| Earning Date | 03-10-2026 | 03-10-2026 |
| Dividend Yield | N/A | ★ 2.95% |
| EPS Growth | ★ 60.71 | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | ★ $403,135,000.00 | $385,088,209.00 |
| Revenue This Year | $2.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.57 |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.73 | $3.93 |
| 52 Week High | $4.18 | $9.39 |
| Indicator | ESPR | PANL |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 35.56 |
| Support Level | $2.37 | $6.59 |
| Resistance Level | $3.02 | $7.42 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 53.47 | 30.43 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk logistics and transportation services. It transports various drybulk cargoes including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The company provides ocean transportation services to clients utilizing an ocean-going fleet of motor vessels in the Handymax, Supramax, Ultramax, Panamax, and Post-Panamax segments. Its services include cargo loading, cargo discharge, vessel chartering, voyage planning, and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters. Geographically, it derives key revenue from the United States, followed by Canada, Germany, and others.